(0.27%) 5 145.50 points
(0.30%) 38 555 points
(0.36%) 17 910 points
(-0.82%) $83.16
(1.35%) $1.949
(-0.12%) $2 344.40
(0.20%) $27.59
(0.85%) $929.90
(-0.32%) $0.932
(-0.38%) $10.98
(-0.42%) $0.797
(0.25%) $92.11
3.38% $ 19.28
Live Chart Being Loaded With Signals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome...
Stats | |
---|---|
Volumen de hoy | 228 560 |
Volumen promedio | 508 465 |
Capitalización de mercado | 2.46B |
EPS | $0 ( 2024-02-21 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.07 |
ATR14 | $0.0170 (0.09%) |
Volumen Correlación
Neuren Pharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Neuren Pharmaceuticals Correlación - Moneda/Commodity
Neuren Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $231.93M |
Beneficio Bruto: | $205.17M (88.47 %) |
EPS: | $1.240 |
FY | 2023 |
Ingresos: | $231.93M |
Beneficio Bruto: | $205.17M (88.47 %) |
EPS: | $1.240 |
FY | 2022 |
Ingresos: | $14.55M |
Beneficio Bruto: | $14.54M (99.93 %) |
EPS: | $0.00150 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.0728 |
Financial Reports:
No articles found.
Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico